Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by research analysts at Berenberg Bank in a research note issued on Tuesday. They presently have a GBX 5,800 ($75.71) target price on the biopharmaceutical company’s stock. Berenberg Bank’s price objective would indicate a potential upside of 13.55% from the stock’s current price.

A number of other brokerages have also issued reports on SHP. HSBC lowered Shire PLC to a “hold” rating and decreased their price objective for the stock from GBX 5,400 ($70.49) to GBX 5,250 ($68.53) in a report on Monday. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Shire PLC in a report on Friday, September 23rd. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a report on Tuesday. Shore Capital reissued a “buy” rating on shares of Shire PLC in a report on Friday, August 12th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a GBX 6,000 ($78.32) price objective on shares of Shire PLC in a report on Monday, September 19th. One analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Shire PLC presently has a consensus rating of “Buy” and a consensus price target of GBX 5,828 ($76.07).

Shire PLC (LON:SHP) opened at 5108.00 on Tuesday. The firm’s market capitalization is GBX 34.88 billion. The stock has a 50 day moving average price of GBX 4,990.28 and a 200-day moving average price of GBX 4,501.92. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00.

The firm also recently announced a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be issued a GBX 3.51 ($0.05) dividend. The ex-dividend date is Thursday, September 8th. This represents a dividend yield of 0.07%.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.